

Oklahoma Health Care Authority

Drug Utilization Review Board (DUR Board)

Meeting – July 8, 2026 @ 4:00pm

at the

Oklahoma Health Care Authority (OHCA)

4345 N. Lincoln Blvd.

Oklahoma City, Oklahoma 73105

NOTE: *The DUR Board will meet at 4:00pm at OHCA (see address above). There will be Zoom access to this meeting; however, Zoom access will be set up in view-only mode with no voting, speaking, video, or chat box privileges. Zoom access will allow for viewing of the presentation slides as well as audio of the presentations and discussion during the meeting; however, the DUR Board meeting will not be delayed or rescheduled due to any technical issues that may arise.*

AGENDA

Discussion and action on the following items:

Items to be presented by Dr. Haymore, Chairman:

1. Call to Order

A. Roll Call – Dr. Wilcox

DUR Board Members:

Dr. Cassidy Blaiss –	participating in person
Ms. Jennifer Boyett –	participating in person
Dr. Christen Ground –	participating in person
Dr. Bret Haymore –	participating in person
Dr. Bethany Holderread –	participating in person
Dr. Matt John –	participating in person
Dr. Craig Kupiec –	participating in person
Dr. Lee Muñoz –	participating in person
Dr. Edna Patatanian –	participating in person
Dr. Jennifer Weakley –	participating in person

Viewing Access Only via Zoom:

Please register for the meeting at:

https://oklahoma.zoom.us/webinar/register/WN_eBUt3qLzSkycOdDyUyZx5g

After registering, you will receive a confirmation email containing information about joining the webinar.

Or join by phone:

Dial: +1-602-753-0140 or +1-669-219-2599

Webinar ID: 910 6408 1365

Passcode: 44589980

Public Comment for Meeting:

- Speakers who wish to sign up for public comment at the OHCA DUR Board meeting may do so in writing by visiting the DUR Board page on the OHCA website at www.oklahoma.gov/ohca/about/boards-and-committees/drug-utilization-review/dur-board and completing the [Speaker Registration Form](#). Completed Speaker Registration forms should be submitted to DURPublicComment@okhca.org. Forms must be received after the DUR Board agenda has been posted and no later than 24 hours before the meeting.
- The DUR Board meeting will allow public comment and time will be limited to 40 minutes total for all speakers during the meeting. Each speaker will be given 5 minutes to speak at the public hearing. If more than 8 speakers properly request to speak, time will be divided evenly.
- Only 1 speaker per manufacturer will be allowed.
- Any speakers who sign up for public comment must attend the DUR Board meeting in person at OHCA (see above address). Public comment through Zoom will not be allowed for the DUR Board meeting.
- In lieu of speaking at the DUR Board meeting, written correspondence by members or providers may be submitted to DURPublicComment@okhca.org. Other written correspondence is not permitted.

Items to be presented by Dr. Haymore, Chairman:

2. Public Comment Forum

- A. Acknowledgement of Speakers for Public Comment

Items to be presented by Dr. Haymore, Chairman:

3. Action Item – Approval of DUR Board Meeting Minutes – See Appendix A

- A. June 10, 2026 DUR Board Meeting Minutes
- B. June 10, 2026 DUR Board Recommendations Memorandum

Non-presentation items reviewed by Dr. DeRemer, Dr. Haymore, Chairman:

4. Update on Medication Coverage Authorization Unit – See Appendix B

- A. Pharmacy Help Desk Activity for June 2026
- B. Medication Coverage Activity for June 2026

Items to be presented by Dr. Travers, Dr. Haymore, Chairman:

5. Chronic Medication Adherence (CMA) Program Update – See Appendix C

- A. CMA Prescriber Mailing Summary
- B. Mailing Summaries
- C. Star Ratings
- D. Provider Summary Report
- E. CMA Trends
- F. Conclusions

Items to be presented by Dr. Moss, Dr. Haymore, Chairman:

6. Action Item – Vote to Prior Authorize Nereus™ (Tradipitant) and Posfrea™ (Palonosetron Injection) and Update the Approval Criteria for the Anti-Emetic Medications – See Appendix D

- A. Market News and Updates
- B. Nereus™ (Tradipitant) Product Summary
- C. Cost Comparison: Palonosetron Products
- D. College of Pharmacy Recommendations

Items to be presented by Dr. O'Halloran, Dr. Haymore, Chairman:

7. Action Item – Vote to Prior Authorize Bysanti™ (Milsaperidone) and Update the Approval Criteria for the Atypical Antipsychotic Medications – See Appendix E

- A. Market News and Updates
- B. Bysanti™ (Milsaperidone) Product Summary
- C. Cost Comparison: Atypical Antipsychotics for Adjunct Treatment of MDD
- D. College of Pharmacy Recommendations

Items to be presented by Dr. DeRemer, Dr. Haymore, Chairman:

8. Action Item – Vote to Prior Authorize Hepcludex® (Bulevirtide-gmod), Relenza® (Zanamivir Inhalation Powder), and Xofluza® (Baloxavir) and Update the Approval Criteria for the Antiviral Medications – See Appendix F

- A. Market News and Updates
- B. Hepcludex® (Bulevirtide-gmod) Product Summary
- C. Cost Comparison: Oral Influenza Antiviral Medications
- D. College of Pharmacy Recommendations

Items to be presented by Dr. Grimes, Dr. Haymore, Chairman:

9. Action Item – Vote to Prior Authorize Prior Authorize Loargys® (Pegzilarginase-nbln) and Update the Approval Criteria for the Urea Cycle Disorder (UCD) Medications – See Appendix G

- A. Market News and Updates
- B. Loargys® (Pegzilarginase-nbln) Product Summary
- C. College of Pharmacy Recommendations

Items to be presented by Dr. Moss, Dr. Haymore, Chairman:

10. Action Item – Vote to Prior Authorize Averi™ (Desogestrel/Ethinyl Estradiol/Ferrous Bisglycinate), Cafergot® (Ergotamine/Caffeine Tablet), Desmoda™ (Desmopressin Oral Solution), Dicyclomine 40mg Tablet, Griseofulvin Ultramicrosize 165mg Tablet, Hydroxyzine Oral Solution Unit Dose Cups (UDCs), Khindivi™ (Hydrocortisone Oral Solution), Migergot® (Ergotamine/Caffeine Suppository), Ontralgy™ (Tizanidine Oral Solution), PoKonza™ (Potassium Chloride 10mEq/15mL Oral Solution), PoKonza™ (Potassium Chloride 15mEq Packet), Potassium Chloride 40mEq Packet,

Quiofic™ (Folic Acid Oral Solution), Relgaabi™ (Gabapentin 200mg Capsule), and Vykoura™ (Leucovorin Injection) – See Appendix H

- A. Introduction
- B. Product Summaries
- C. College of Pharmacy Recommendations

Items to be presented by Dr. Sinko, Dr. Haymore, Chairman:

11. Action Item – Vote to Prior Authorize Inlexzo™ (Gemcitabine Intravesical System), Kyxata™ (Carboplatin), Lifyorli™ (Relacorilant), and ZUSDURI™ (Mitomycin Intravesical Solution) and Update the Approval Criteria for the Genitourinary and Gynecologic Cancer Medications – See Appendix I

- A. Market News and Updates
- B. Product Summaries
- C. Cost Comparison: Carboplatin Products
- D. College of Pharmacy Recommendations

Items to be presented by Dr. DeRemer, Dr. Haymore, Chairman:

12. Action Item – Annual Review of Anti-Ulcer Medications – See Appendix J

- A. Current Prior Authorization Criteria
- B. Utilization of Anti-Ulcer Medications
- C. Prior Authorization of Anti-Ulcer Medications
- D. Market News and Updates
- E. College of Pharmacy Recommendations
- F. Utilization Details of Anti-Ulcer Medications

Items to be presented by Dr. Moss, Dr. Haymore, Chairman:

13. Action Item – Annual Review of Epidermolysis Bullosa (EB) Medications – See Appendix K

- A. Current Prior Authorization Criteria
- B. Utilization of EB Medications
- C. Prior Authorization of EB Medications
- D. Market News and Updates
- E. College of Pharmacy Recommendations
- F. Utilization Details of EB Medications

Items to be presented by Dr. Sinko, Dr. Haymore, Chairman:

14. Annual Review of Colorectal Cancer (CRC) Medications and 30-Day Notice to Prior Authorize Jobevne™ (Bevacizumab-nwgd) – See Appendix L

- A. Current Prior Authorization Criteria
- B. Utilization of CRC Medications
- C. Prior Authorization of CRC Medications
- D. Market News and Updates
- E. Cost Comparison: Bevacizumab Products
- F. College of Pharmacy Recommendations
- G. Utilization Details of CRC Medications

Items to be presented by Dr. O'Halloran, Dr. Haymore, Chairman:

15. Annual Review of Anti-Diabetic Medications and Kerendia® (Finerenone) and 30-Day Notice to Prior Authorize Awiqli® (Insulin Icodec-abae), Glipizide 15mg Tablet, Kirsty™ (Insulin Aspart-xjhz), and Langlara™ (Insulin Glargine-aldy) – See Appendix M

- A. Current Prior Authorization Criteria
- B. Utilization of Anti-Diabetic Medications and Kerendia® (Finerenone)
- C. Prior Authorization of Anti-Diabetic Medications and Kerendia® (Finerenone)
- D. Market News and Updates
- E. Awiqli® (Insulin Icodec-abae) Product Summary
- F. College of Pharmacy Recommendations
- G. Utilization Details of Anti-Diabetic Medications and Kerendia® (Finerenone)

Items to be presented by Dr. Grimes, Dr. Haymore, Chairman:

16. Annual Review of Heart Failure (HF) Medications and 30-Day Notice to Prior Authorize Enbumyst™ (Bumetanide Nasal Spray), Lasix® ONYU (Furosemide On-Body Infusor), and Myqorzo™ (Aficamten) – See Appendix N

- A. Current Prior Authorization Criteria
- B. Utilization of HF Medications
- C. Prior Authorization of HF Medications
- D. Market News and Updates
- E. Product Summaries
- F. College of Pharmacy Recommendations
- G. Utilization Details of HF Medications

Items to be presented by Dr. Dorsey, Dr. Haymore, Chairman:

17. Annual Review of Alzheimer's Disease Medications and 30-Day Notice to Prior Authorize Leqembi® Iqlik™ (Lecanemab-irmb) – See Appendix O

- A. Current Prior Authorization Criteria
- B. Utilization of Alzheimer's Disease Medications
- C. Prior Authorization of Alzheimer's Disease Medications
- D. Market News and Updates
- E. College of Pharmacy Recommendations
- F. Utilization Details of Alzheimer's Disease Medications

Non-presentation items reviewed by Dr. Wilson, Dr. Haymore, Chairman:

18. Annual Review of Testosterone Products – See Appendix P

- A. Current Prior Authorization Criteria
- B. Utilization of Testosterone Products
- C. Prior Authorization of Testosterone Products
- D. Market News and Updates
- E. College of Pharmacy Recommendations
- F. Utilization Details of Testosterone Products

Non-presentation items reviewed by Dr. DeRemer, Dr. Haymore, Chairman:

19. U.S. Food and Drug Administration (FDA) and Drug Enforcement Administration (DEA) Updates – See Appendix Q

Items to be presented by Dr. Adams, Dr. Haymore, Chairman:

20. Future Business* (Upcoming Product and Class Reviews)

There is not a live DUR Board Meeting scheduled for August 2026. August 2026 will be a packet-only meeting.

- A. Copper Metabolism Disorder Medications
- B. Iron Chelating Agents
- C. Iron Products
- D. Miscellaneous Cancer Medications
- E. Opioid Analgesics and Medication-Assisted Treatment (MAT) Medications
- F. Topical Corticosteroids
- G. Various Systemic Antibiotics

*Future product and class reviews subject to change.

21. Adjournment

NOTE: An analysis of the atypical [Aged, Blind, and Disabled (ABD)] patient subgroup of the Oklahoma Medicaid population has been performed pertaining to all recommendations included in this DUR Board meeting packet to ensure fair and knowledgeable deliberation of the potential impact of the recommendations on this patient population.

NOTE: Oklahoma Medicaid transitioned from a fee-for-service (FFS) pharmacy benefit to a managed care pharmacy benefit for most members on April 1, 2024. At that time, the majority of SoonerCare members were transitioned to one of the three managed care SoonerSelect plans: Aetna, Humana, or Oklahoma Complete Health. SoonerSelect data has been provided to the College of Pharmacy and has been used in analyses throughout this DUR Board meeting packet. The data included in this DUR Board meeting packet combines FFS and managed care utilization data. The managed care utilization and prior authorization (PA) data reported in this packet is based solely on the data provided by the SoonerSelect plans.